血管内皮生长因子重组DNA的构建及体外表达

目的:以质粒PCNDA3.0为载体,研究血管内皮生长因子(VEGF)目的基因在体外真核细胞中的表达.方法:将编码人可溶性VEGF165的目的基因克隆于带有CMV启动子/增强子的PCNDA3.0载体上,重组为PCNDA3.0-VEGF165质粒载体.直接以质粒DNA形式应用脂质体介导的方法转染人脐静脉内皮细胞ECV304,收取细胞上清,用ELISA和Western blot方法检测上清中VEGF165可溶性表达产物.结果:VEGF165基因在CMV启动子/增强子的调控下,可在ECV304细胞高效表达,且在转染后72 h表达量明显高于转染后48 h的表达.结论:以质粒PCNDA3.0为载体,VEGF165基因可以在体外真核细胞中表达,为治疗缺血性疾病提供一个新的基因治疗途径.     

腺病毒介导的生长抑制基因4对ECV304细胞体外生长及分泌血管内皮生长因子的影响

目的: 检测腺病毒介导的生长抑制基因4(adenovirus-mediated inhibitor of growth family member 4,Ad-ING4)感染后ECV304细胞体外生长及分泌血管内皮生长因子(vascular endothelial growth factor,VEGF)的影响,探讨ING4抑制肿瘤生长的可能机制。方法: 构建ING4腺病毒载体,用MTT法检测Ad-ING4感染后ECV304细胞体外生长影响,ELISA检测VEGF的分泌情况。结果: Ad-ING4感染后第3天和第4天ECV304细胞体外生长均受到抑制(P < 0.01),第4天时抑制率达63.6%,VEGF分泌受到抑制。结论: ING4能抑制ECV304细胞生长及VEGF分泌。Ad-ING4能抑制血管内皮细胞生长和血管的生成,从而可抑制体内肿瘤的生长。     

血管内皮生长因子基因对人骨髓基质细胞增殖及代谢的影响

目的 观察血管内皮生长因子(VEGF)基因对人骨髓基质细胞(hBMSc)增殖、代谢的影响.方法 实验分为3组:①VEGF165和eGFP基因转染hBMSc组;②空腺病毒载体转染hBMSc组;③单纯hBMSc组.培养细胞,进行MTT检测,流式细胞仪分析细胞周期.取各组生长状态良好的第3代细胞,转染后,进行ALP含量检测,骨钙蛋白和层粘连蛋白榆测.结果 各组细胞数量随培养时间的延长都有所增加,各时间点经VEGF165基因转染的hBMSc吸光度值无显著性差异(p>0.05).经转染基因的hBMSc与转染空载体、未转染的hBMSc相比较,DNA合成前期细胞所占百分比无显著性差异,反应增殖活力的增殖指数PrI(包括DNA合成期、DNA合成后期和有丝分裂期)也无显著性差异(P>0.05).经转染的hBMSc碱性磷酸酶、骨钙蛋白和层粘连蛋白合成与转染空载体、未转染的hBMSc相比较有显著性差异(P<0.05),证实经转染的hBMSc碱性磷酸酶、骨钙蛋白和层枯连蛋白合成明显高于其他两组.结论 本实验证实了构建的Ad-VEGF165感染哺乳动物细胞后具有分泌VEGF165的能力,并获得了转VEGF165基因hBMSc.转染VEGF165对hBMSc体外增殖明显影响,同时可以显著提高BMSc分泌ALP,骨钙素(OC)和层粘连蛋白(LN),说明VEGF165对hBMSc体外向成骨细胞分化起到了促进作用.     

阿魏酸钠对小鼠H22肝癌生长的抑制作用及其机制研究

目的 观察注射用阿魏酸钠对小鼠H22肝癌生长及血管生成抑制作用及其对血管内皮生长因子(VEGF)Mrna转录的影响.方法 昆明小鼠前腋下皮下接种H22小鼠肝癌细胞,腹腔注射阿魏酸钠,每3 d测量1次肿瘤体积.用免疫组化法测定VEGF及增殖细胞核抗原(PCNA)的表达.MTT法检测阿魏酸钠对H22肿瘤细胞及血管内皮细胞(ECV304)增殖的影响,RT-PCR法测定肿瘤组织的VEGF Mrna的转录.结果 阿魏酸钠组小鼠H22肿瘤体积、重量增长明显较对照组缓慢(P＜0.05),同时阿魏酸钠组的肿瘤微血管密度及VEGF、PCNA阳性细胞较对照组显著减少(P＜0.05).阿魏酸钠组VEGF Mrna转录比对照组显著减少(P＜0.05).体外实验,阿魏酸钠对ECV304及H22细胞的增殖均无显著抑制作用.结论 阿魏酸钠可以显著抑制小鼠H22肿瘤的生长及血管生成,且能抑制VEGF的表达,但不能抑制ECV304及H22细胞的增殖.阿魏酸钠对肿瘤组织VEGF表达的抑制作用可能是其抗H22肿瘤及抗血管生成的一个重要机制.     

蜂毒素体外抑制内皮细胞血管生成及其作用机制

目的:探讨蜂毒素对人脐静脉来源内皮细胞(ECV304)血管生成的抑制作用及其机制.方法:体外培养ECV304细胞,分别测定蜂毒素对其增殖、迁移及形成管状结构的影响.采用酶联免疫吸附法检测血管内皮细胞生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)的含量.应用实时荧光定量PCR方法检测ECV304细胞VEGF mRNA和bFGF mRNA的表达.结果:经蜂毒素作用后,ECV304细胞的增殖明显受到抑制,24,48,72 h的IC50分别为5.11,4.68,4.40 mg/L.蜂毒素低、中、高浓度组和沙利度胺(TLD)组ECV304细胞迁移数目(19.44±6.54),(11.17±2.85),(4.22±1.83)和(18.28±5.29)个,明显低于空白对照组(42.33±9.63 )个(P＜0.01).蜂毒素低、中、高浓度组及TLD组形成管状结构的面积分别为 (5947.22±973.72),(1558.33±281.06),(705.85±318.01)和(2928.92±735.67) μm2/视野,均低于空白对照组(7828.94±1202.54) μm2/视野(P＜0.01).经蜂毒素处理后,ECV304细胞分泌VEGF及bFGF的功能明显下降.荧光定量PCR证实,蜂毒素可降低ECV304细胞VEGF mRNA和bFGF mRN的表达.结论:体外实验结果表明,蜂毒素具有抑制ECV304细胞血管生成的作用,这种效应与血管内皮细胞VEGF和bFGF的活性降低及其合成受到抑制有关.     

血管内皮生长因子及其Flt-1受体在白血病细胞中的表达

目的探讨人白血病细胞系血管内皮生长因子(VEGF)及其Fh-1受体的表达,进一步阐明VEGF在白血病细胞异常增殖中的作用机制.方法以人脐静脉血管内皮细胞系ECV304作为对照,采用RT-PCR半定量技术和免疫组化检测体外培养的人白血病细胞系K562和HL-60中VEGF及Flt-1的表达.采用MTT试验观察VEGF反义寡核苷酸(VEGF-AS)对白血病细胞体外增殖的影响.结果K562和HL-60细胞同时表达VEGF和Fh-1 mRNA和蛋白.VEGF-AS能够抑制白血病细胞体外增殖.结论在白血病细胞异常增殖中自分泌VEGF可能起着重要作用.     

VEGF基因在兔骨髓基质细胞中的表达及活性测定

目的探讨人血管内皮细胞生长因子(VEGF)基因修饰的兔骨髓基质细胞对VEGF基因的表达及表达产物的生物学活性.方法制备真核表达质粒pAdCMV-VEGF165,以Superfect转染试剂介导VEGF基因转染兔骨髓基质细胞,收获转染后24h至6d的转染上清和细胞,采用RT-PCR技术、免疫组化SABC法检测转染细胞中外源性VEGF165基因的转录及表达,用血管内皮细胞增殖试验测定转染细胞培养上清中VEGF的生物活性.结果VEGF基因转染的兔骨髓基质细胞可有效转录VEGF165,其分泌于培养上清中的表达产物可促进血管内皮细胞增殖,具有很强的生物活性.结论VEGF基因转染的兔骨髓基质细胞可有效表达具有生物活性的VEGF.     

VEGF165反义RNA表达对人胃癌细胞恶性生物学行为的影响

目的利用本室构建的反义VEGF165（血管内皮生长因子,vascular endothelial growth factor）真核表达载体,研究VEGF反义RNA表达对人胃癌细胞生物学表型的影响. 方法用阳性脂质体介导的基因转染技术,将VEGF反义RNA重组体转入人胃癌细胞系,观察转染细胞的细胞周期、增殖能力及致瘤生长情况等生物学表现. 结果 VEGF反义RNA重组体转染胃癌细胞后,斑点杂交、间接免疫荧光等分析显示,反义RNA基因转染技术可使VEGF的表达明显减弱;与未转染的细胞相比,G2/M期细胞增加(0.39),而S期细胞减少(0.54);克隆形成率(2.2%)低于未转染细胞(4.0%);肿瘤细胞接种裸鼠后33 d时,VEGF反义RNA表达人胃癌细胞所致的移植瘤体积（345±136) mm3明显小于未转染细胞所致的移植瘤体积（1534±363) mm3. 结论 VEGF反义RNA可以通过抑制肿瘤组织血管生成而防治肿瘤的生长,另外VEGF的表达可能与细胞增殖能力有关.     

重组腺病毒介导血管内皮生长因子基因在骨髓间充质干细胞中的表达及其影响

目的观察重组腺病毒介导血管内皮生长因子基因(AdVEGF165)转染后大鼠骨髓间充质干细胞(BMSCs)中血管内皮生长因子的表达情况以及腺病毒载体对大鼠骨髓间充质干细胞的生长影响情况。方法体外培养大鼠骨髓间充质干细胞,用腺病毒载体转染BMSCs。采用ELISA法检测血管内皮生长子因子(VEGF)的表达和分泌。转染后用胰酶消化传代培养,MTT法绘制细胞生长曲线。结果AdVEGF165转染组上清液中VEGF蛋白表达量极显著高于空白对照组(P<0.01)。且AdVEGF165转染BMSCs后,生长曲线与正常培养细胞无显著差异(P>0.05)。结论重组腺病毒载体能够在BMSCs中介导VEGF的表达,且对BMSCs生长无影响。     

人VEGF165基因转染兔骨髓内皮祖细胞及对其增殖的影响

目的 探讨人血管内皮生长因子165(hVEGF165)基因转染兔骨髓源性内皮祖细胞(EPCs)及对EPCs增殖的影响.方法 体外分离、培养、扩增并鉴定EPCs,脂质体介导转染携带增强型绿色荧光蛋白标记的VEGF165质粒、空白质粒,同时经ELISA法检测转基因EPCs表达VEGF蛋白,并采用CCK-8法检测对其增殖的影响.结果 FITC标记荆豆凝集素Ⅰ和Dil标记的乙酰化低密度脂蛋白荧光双染证实正在分化的EPCs,同时经免疫组化法证实VEGF受体2 FLk-1和Ⅷ因子的表达;VEGF165质粒转染组EPCs上清液中表达VEGF165,VEGF165转染EPCs的转染率约22.5%;hVEGF165基因转染促进EPCs增殖.结论 hVEGF165基因可成功转染EPCs,且可促进EPCs的增殖,为基因治疗血管性疾病提供了动物实验基础.     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…